Breaking News

Baxter Acquires Hemophilia Assets

January 24, 2013

Gains investigational compound OBI-1 and related assets

Baxter International has agreed to acquire the investigational hemophilia compound OBI-1 and related assets from Inspiration BioPharmaceuticals, in conjunction with Inspiration’s ongoing bankruptcy proceedings. The transaction, which includes manufacturing operations from Ipsen Pharma, is subject to regulatory approvals.
 
Baxter will make an upfront payment of $50 million and may make payments of as much as $20 million based on regulatory approval in the U.S. and its first additional country. Additional amounts may be paid upon approval of additional indications, sales payments and milestones when sales exceed $100 million. 
 
OBI-1 is a recombinant porcine factor VIII (rpFVIII) being investigated for the treatment of bleeding in people with acquired hemophilia A and congenital hemophilia A patients with inhibitors. OBI-1 is currently in Phase III studies and has received orphan drug designation in the U.S. and Europe, and was recently granted fast track designation by the FDA.
 
“OBI-1 has the potential to address existing unmet needs of hemophilia patients and is a strong strategic fit with Baxter’s current hemophilia portfolio,” said Bruce Ewenstein, M.D., Ph.D., vice president of clinical affairs in Baxter’s BioScience business.

Related Contract Manufacturing:

blog comments powered by Disqus
  • Solid Dispersions

    Solid Dispersions

    Robert Harris, Juniper Pharma Services||April 5, 2016
    A universal formulation strategy for poorly soluble drugs?

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • CMC Biologics: Growing Through Innovation

    Tim Wright, Editor||January 28, 2016
    The new chief exec talks about industry trends and growth plans.